- New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer —
- MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies —
HUTCHMED Reports TAGRISSO Plus ORPATHYS Showed Clinically Meaningful Responses In Lung Cancer Patients With High MET Overexpression Or Amplification In The SAVANNAH Phase II Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated